We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Urine Test Evaluated for Schistosomiasis Diagnosis

By LabMedica International staff writers
Posted on 08 Dec 2011
Urine circulating cathodic-antigen (CCA) tests are available for diagnosing schistosomiasis in endemic areas. More...


The accuracy of a commercially available CCA cassette test (designated CCA-A) and an experimental formulation (CCA-B) have been assessed for diagnostic accuracy for Schistosoma mansoni.

A cross-sectional survey was carried out by scientists at the Swiss Tropical and Public Health Institute (Basel, Switzerland) in three settings of Côte d'Ivoire, where local investigators collaborated. Two of the settings designated A and B, are endemic for S. mansoni, whereas S. haematobium coexists in the third setting, designated C. Overall, 446 children, aged 8–12 years, submitted multiple stool and urine samples.

For S. mansoni diagnosis, stool samples were examined with triplicate Kato-Katz thick smears, whereas urine samples were tested with CCA-A (Rapid Medical Diagnostics; Pretoria, South Africa). The first stool and urine samples were additionally subjected to an ether-concentration technique and CCA-B, respectively. Urine samples were examined for S. haematobium using a filtration method, and for microhematuria using Hemastix dipsticks (Siemens Healthcare Diagnostics GmbH; Eschborn, Germany).

The sensitivity of triplicate Kato-Katz from the first stool and a single CCA-A test was 47.9% and 56.3% (setting A), 73.9% and 69.6% (setting B), and 94.2% and 89.6% (setting C). The respective sensitivity of a single CCA-B was 10.4%, 29.9%, and 75.0%. The specificity of CCA-A test was moderate (76.9%-84.2%); while the CCA-B assay was high (96.7%-100%). A concurrent S. haematobium infection or the presence of microhematuria did not influence the CCA-A test results for S. mansoni diagnosis.

The authors concluded that in the current study area of south Côte d'Ivoire, where the prevalence and intensity of S. mansoni are still high, partially explained by the prior lack of control efforts, the CCA-A can become a useful method for S. mansoni diagnosis in health centers at the periphery and schistosomiasis control programs. On the other hand, while the specificity of the CCA-B test was high, its current formulation cannot be recommended for S. mansoni diagnosis. The study was published November 2011 in the online journal Public Library of Science Neglected Tropical Disease.

Related Links:

Swiss Tropical and Public Health Institute
Rapid Medical Diagnostics
Siemens Healthcare Diagnostics GmbH



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.